A diabetes drug may cut the risk of certain skin cancers, study finds
Metformin is a medication prescribed to help manage type 2 diabetes. Recent research suggests, however, this medication may potentially decrease risk of certain types of skin cancer.
A retrospective case-control study published in the Journal of Drugs in Dermatology explored whether metformin could reduce the risk of non-melanoma skin cancers, specifically basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
What the research says
Researchers analyzed data from the All of Us research database, which compiles health information from a diverse group of participants, to assess the potential impact of metformin on these two cancers.
Metformin reduced the risk of basal cell carcinoma across all sex and ethnicity groups, the researchers found.
For squamous cell carcinoma patients, though, the lines weren't as clear. In some cases, metformin users saw a significantly lower risk of squamous cell carcinoma, but that reduction was not significant in African American patients.
The results suggest metformin may offer protective benefits against certain types of non-melanoma skin cancers, though its effectiveness may vary among different populations.
It is important to note that metformin's effect on skin cancer is controversial and researchers do not yet understand how it might work to reduce the risk of certain skin cancers.
Other studies have found that metformin may have an anti-inflammatory effect that lowers the risk of certain skin cancers, but we do not know this for certain.
Side effects of metformin
Metformin is generally considered safe and well-tolerated by most people, though side effects like nausea, vomiting and diarrhea may occur in up to 30% of people taking this medication. Less frequent side effects can include chest discomfort, weakness, headache, rhinitis, hypoglycemia and vitamin B12 deficiency (with long-term metformin use).
A rare but serious side effect is lactic acidosis, with risk factors being older age, having a history of alcoholism and hepatic and/or renal impairment.
Who might benefit?
More research is needed to determine exactly how metformin may or may not help to reduce skin cancer risk. Based on the current evidence we do have, my advice is to discuss the use of metformin with your doctor if you have a history of multiple skin cancers and also a history of high blood sugar.
I'm still on sabbatical and no longer run Baumann Cosmetic Institute, so please follow @SkinTypeSolutions on social media, or visit LeslieBaumannMD.com if you have questions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan Drug Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880). The Company, in December 2024, received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The product development plan is designed to seek concurrence of the FDA under MUMS designation. MUMS is a status similar to Orphan Drug status for human drugs. It entitles the Company to an extended 7-year period of exclusive marketing following approval or conditional approval, provided that the Company meets all requirements for maintaining the designation. Doxorubicin-containing microneedle array (D-MNA) is a patent protected dissovable transdermal patch with cellulose based microneedle arrays that are tip-loaded with doxorubicin. After application, the microneedles function by penetrating the strateum corneum layer of the skin, create a temporary microchannel, penetrate the tumor, dissolve and release doxorubicin into the target tumor, and eradicate the cancer cells. "In Veterinary Medicine, where there are only a handful of approved oncology drugs, we believe developing a non-invasive treatment for equine SCC represents an untapped and unmet market opportunity potentially in the range of $250 million," stated Dr. Raza Bokhari, Executive Chairman & CEO. "The submission to the FDA of a novel product development program may provide us a first mover advantage and sets the stage to consider other companion animal species and types of cancer." Squamous Cell Carcinoma (SCC) in Horses SCC is a mucocutaneous skin tumor in horses, primarily affecting adult or aged horses with white or partially white coats. Breeds like Appaloosa, Belgian, American Paint, and Pinto are particularly susceptible. SCC often develops in areas with minimal pigmentation and sparse hair, notably around mucous membranes. More specifically, tumors are mainly seen around the eyes, lips, nose, anus, and external genitalia. The overall incidence of SCC is 2-3% and recent estimates of the US horse population range from 6.6 to 7.25 million horses. Current treatment includes surgery to remove the largest mass, cryotherapy of the smaller mass, and local injection of a chemotherapy drug. In some cases, a topical chemotherapeutic drug will be prescribed in the form of drops (tumors near the eye) or cream (tumors in other parts of body). Additionally, some horses are put on an oral drug called piroxicam that may slow the return of the cancerous cells. Product Development Plan The clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 50 horses presenting with external SCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The horses will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The horses will be assessed for outcomes over six (6) months from index dose. The primary effectiveness variable will be a veterinarian's assessment for complete clinical response of the target tumor at day 90 according to RECIST. The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability human study (SKNJCT-001) completed in March 2021. SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC. The Company also has SKNJCT-003 Phase 2 clinical study currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The Company also announced expanding clinical trial sites in Europe. The Company also has a clinical design (SKNJCT-004) currently underway in United Arab Emirates (UAE). The study is expected to randomize 36 patients in four sites in UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. In April 2025, the Company announced entering into a binding letter of intent to acquire Antev Ltd. ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. For further information contact: Carolyn Bonner, President(610) 636-0184cbonner@ Anna Baran-Djokovic, SVP Investor Relations(305) 615-9162adjokovic@ About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE. In April 2025, the Company also announced entering into a binding letter of intent to acquire Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding its comprehensive product development plan to treat external SCC for horses, the commencement of its development plan, the market opportunity a non-invasive treatment for equine SCC and the Company's opportunity to develop, gain approval for and commercialize its product to meet such opportunity, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company's intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at and on SEDAR+ at . Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. To view the source version of this press release, please visit
Yahoo
3 days ago
- Yahoo
Common Diabetes Drug Linked to 'Exceptional Longevity' in Women
Not only can the drug metformin help to effectively manage type 2 diabetes, it may also give older women a better chance of living to the grand old age of 90, according to new research – thanks, it seems, to a variety of anti-aging effects. The research used data from a long-term US study of postmenopausal women. Records on a total of 438 women were picked out – half who took metformin for their diabetes, and half who took a different diabetes drug, called sulfonylurea. While there are a lot of caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. "Metformin has been shown to target multiple pathways of aging and therefore has been postulated as a drug that may extend human longevity," write the researchers in their published paper. "We found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes." We already know quite a lot about metformin. It's been around for decades, and is considered a gerotherapeutic: a drug able to slow down various aging processes in the body. For example, it's been shown to limit DNA damage and promote gene activity associated with long life. Previous studies have shown metformin can put the brakes on wear and tear in the brain, and even reduce the risk of long COVID. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. This research can't prove cause and effect like a randomized control trial (RCT) might be able to, because the participants weren't randomly assigned to one treatment or the other – rather, they were following professional advice. What's more, there was no placebo group given no treatment at all. The overall sample size wasn't particularly large, either. However, the study also has its strengths – not least the average 14 to 15 years of follow-up, which goes way beyond the length a standard RCT would be able to. That's important when you're trying to see how lifespan is affected. "A key advantage of our analysis was the long follow-up period after treatment initiation enabled by examination of a cohort with extensive follow-up from midlife to ages 90 and older, which is not feasible in typical randomized controlled trials," write the researchers. RCTs could be something that follows further down the line to dig deeper into these results, the researchers suggest. In the meantime, with the global population continuing to skew older and older, studies continue to find ways of keeping us healthier for longer, and reducing damage to the body as we age. "The geroscience hypothesis posits that biological aging is malleable and that slowing biological aging may delay or prevent the onset of multiple age-related diseases and disability," write the researchers. "A key goal of geroscience is to identify novel therapeutic and preventive interventions that slow biological aging." The research has been published in the Journal of Gerontology: Medical Sciences. Increased Toxicity Risk Identified For Children With ADHD, Autism Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover Texas Woman Dies From Brain-Eating Amoeba After Flushing Sinuses
Medscape
3 days ago
- Medscape
Small Ear-Wax Sample, Big Diagnostic Clues
A recent BBC report suggests that cerumen, commonly known as earwax, may harbor biomarkers to aid in the diagnosis and monitoring of conditions such as cancer, Alzheimer's disease, and metabolic disorders. Cerumen Profile The primary function of cerumen is to keep the external auditory canal clean and lubricated, preventing invasion by bacteria, fungi, and insects. Beyond this, cerumen may reflect systemic metabolism by concentrating a broader array of compounds than blood, urine, sweat, and tears. Its relative stability allows the accumulated cerumen to provide long-term snapshots of metabolic changes. Disease Associations Researchers have defined genetically determined wet and dry cerumen phenotypes. In the US, Caucasian, African American, and German women with wet cerumen faced roughly four times the risk of dying from breast cancer compared with Japanese and Taiwanese women with dry cerumen. The study found that Japanese women with breast cancer were more likely to carry the wet-cerumen allele than were healthy controls. However, large-scale studies in Germany, Australia, and Italy failed to confirm these associations. A recent analysis reported that patients with Ménière's disease had lower levels of three fatty acids in the cerumen compared with healthy controls — the first biomarker identified for that disorder. In a 2019 study led by Nelson Roberto Antoniosi Filho, PhD (Federal University of Goiás Goiânia in Brazil), researchers analyzed cerumen samples from 52 patients with lymphoma, carcinoma, or leukemia and 50 healthy volunteers, using a method that identifies volatile organic compounds (VOCs). The researchers identified 27 VOCs that served as diagnostic fingerprints for cancer, predicting the cancer status with 100% accuracy. The assay could not distinguish among cancer types, indicating that these VOCs represent a general response to malignant cells. Another investigation by the same group showed that cerumen analysis can detect metabolic disturbances in premalignant stages when cells exhibit dysplastic changes that may lead to cancer but remain nonmalignant, potentially enabling much earlier intervention. The team is also investigating whether metabolic alterations caused by neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, can be detected in the cerumen. Diagnostic Tool Antoniosi Filho and colleagues proposed that cancer, as a mitochondrial metabolic disorder, releases VOCs that accumulate in cerumen, allowing differentiation between healthy and cancerous individuals via an assay they call the cerumenogram. The aim was to develop a cerumenogram as a diagnostic tool to accurately predict certain cancers from a small cerumen sample. Clinical Adoption Hospital Amaral Carvalho in Jaú, São Paulo — a national reference center for oncology and bone marrow transplantation — has recently implemented cerumenograms for cancer diagnosis and monitoring. Future Directions An April 2025 paper in Scientific Reports by Antoniosi Filho concluded that the cerumenogram could: 1. Identify oncologic risk by detecting premalignant cells before cancer onset, introducing a novel screening modality 2. Show that mitochondrial impairment in premalignant cells — such as hypermetabolic inflammation and dysplasia — produces the same VOC biomarkers as malignant cells, distinct from those in benign lesions, opening new paths for risk management and early intervention 3. Correlate cerumenogram findings with established imaging techniques such as 2-deoxy-2-[fluorine-18] fluoro-D-glucose PET/CT (18F-FDG PET/CT) and gallium-68 PSMA PET/CT, demonstrating alignment with clinical results while offering a noninvasive, lower-cost alternative 4. Monitor treatment response and cancer remission, supporting assessment of therapeutic efficacy and cellular return to normal 5. Confirm metabolic indicators of malignancy to guide clinical decisions alongside imaging and biopsy 6. Drive the development of targeted therapies aimed at metabolites overproduced in malignant conditions. In conclusion, the cerumenogram may serve as a valuable assay for evaluating precancerous indicators, cancer progression, and remission, with the potential to reduce mortality, alleviate patient suffering, and lower disease-related costs. Congratulations to Nelson Roberto Antoniosi Filho, PhD, and his team.
